Judge Bars Antitrust Claims in MedImmune's Patent Suit Vs. Genentech
In a case with wide-ranging implications for licensing in the biotechnology sector, a U.S. District Court has ruled that MedImmune cannot pursue antitrust claims in its suit to invalidate a patent...To view the full article, register now.
Already a subscriber? Click here to view full article